Estimated Effectiveness News Today

The study in JAMA Network Open evaluates the effectiveness of simultaneously administering the Pfizer-BioNTech BNT162b2 BA.4/5 COVID-19 vaccine and seasonal influenza vaccines versus separate administration. Results suggest similar or slightly increased COVID-19 outcomes and lower influenza-related outcomes with coadministration, particularly in those aged 65 and above.

Recent study assesses NVX-CoV2373 vaccine's effectiveness against Omicron variant. Findings show decreased efficacy over four months, but stable protection against symptomatic COVID-19.

The NVX-CoV2373 COVID-19 vaccine offers significant protection against symptomatic infections, but its effectiveness against SARS-CoV-2 declines within four months, according to a study in JAMA Network Open using Italian data. However, its protection against symptomatic COVID-19 seems to remain stable during this period.

A recent study published in Morbidity and Mortality Weekly Report estimated the efficacy of the JYNNEOS vaccine against mpox.

A study published in JAMA Network Open explores the protective efficacy of previous exposure to omicron subvariants and booster vaccination against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) omicron BA.5 infection.

A new research letter assessed the effectiveness of the mRNA1273 and BNT162b2 vaccines among fully vaccinated male veterans who were 65 years of age or above from July to September 2021.

Researchers from the U.S. Veterans Affairs have examined the U.S. effort to vaccinate its Veteran population to investigate further.